Cargando…

Case Report: Targeting of individual somatic tumor mutations by multipeptide vaccination tailored for HLA class I and II presentation induces strong CD4 and CD8 T-cell responses in a patient with metastatic castration sensitive prostate cancer

Localized prostate cancer is curable, but metastatic castration sensitive prostate cancer has a low 5-year survival rate, while broad treatment options are lacking. Here we present an mCSPC patient under remission receiving individualized neoantigen-derived peptide vaccination as recurrence prophyla...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zelba, Henning, Rabsteyn, Armin, Bartsch, Oliver, Kyzirakos, Christina, Kayser, Simone, Seibold, Marcel, Harter, Johannes, Latzer, Pauline, Hadaschik, Dirk, Battke, Florian, Golf, Alexander, Rettig, Matthew B., Biskup, Saskia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10619716/ https://www.ncbi.nlm.nih.gov/pubmed/37920460 http://dx.doi.org/10.3389/fimmu.2023.1271449

Ejemplares similares

Adjuvant Treatment for Breast Cancer Patients Using Individualized Neoantigen Peptide Vaccination—A Retrospective Observation
por: Zelba, Henning, et al.
Publicado: (2022)

Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report
por: Blumendeller, Carolin, et al.
Publicado: (2021)

Immune monitoring and TCR sequencing of CD4 T cells in a long term responsive patient with metastasized pancreatic ductal carcinoma treated with individualized, neoepitope-derived multipeptide vaccines: a case report
por: Sonntag, Katja, et al.
Publicado: (2018)

Prevention of “Humanized” Diabetogenic CD8 T-Cell Responses in HLA-Transgenic NOD Mice by a Multipeptide Coupled-Cell Approach
por: Niens, Marijke, et al.
Publicado: (2011)

Characterization of a Multipeptide Lantibiotic Locus in Streptococcus pneumoniae
por: Maricic, Natalie, et al.
Publicado: (2016)

Immunoprevention of KRAS-driven lung adenocarcinoma by a multipeptide vaccine
por: Pan, Jing, et al.
Publicado: (2017)

Molecular tumor analysis and liquid biopsy: a feasibility investigation analyzing circulating tumor DNA in patients with central nervous system lymphomas
por: Hickmann, Anne-Katrin, et al.
Publicado: (2019)

Branched multipeptide immunotherapy for glioblastoma using human leukocyte antigen-A*0201-restricted cytotoxic T-lymphocyte epitopes from ERBB2, BIRC5 and CD99
por: Kim, Young-Hee, et al.
Publicado: (2016)

Multipeptide stimulated PBMCs generate T(EM)/T(CM) for adoptive cell therapy in multiple myeloma
por: Vardam-Kaur, Trupti, et al.
Publicado: (2021)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
por: Forschner, Andrea, et al.
Publicado: (2020)

The question of WGS’s clinical utility remains unanswered
por: Battke, Florian, et al.
Publicado: (2021)

Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist
por: Meneveau, Max O, et al.
Publicado: (2021)

Frequencies of CD33+CD11b+HLA-DR–CD14–CD66b+ and CD33+CD11b+HLA-DR–CD14+CD66b– Cells in Peripheral Blood as Severity Immune Biomarkers in COVID-19
por: Alberca, Ricardo Wesley, et al.
Publicado: (2020)

Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma
por: Perales, Miguel-Angel, et al.
Publicado: (2008)

Expression of HLA-I, CD8, and CD4 and Their Clinical Significance in Cervical Cancer
por: Fan, Jiang Tao, et al.
Publicado: (2011)

Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration‐resistant prostate cancer
por: Keresztes, Dávid, et al.
Publicado: (2021)

A multipeptide vaccine plus toll-like receptor agonists LPS or polyICLC in combination with incomplete Freund’s adjuvant in melanoma patients
por: Melssen, Marit M., et al.
Publicado: (2019)

Tolerogenic vaccine composited with islet-derived multipeptides and cyclosporin A induces pTreg and prevents Type 1 diabetes in murine model
por: Zhou, Xian, et al.
Publicado: (2019)

HLA-DR polymorphism affects the interaction with CD4
Publicado: (1995)

Predicting HLA CD4 Immunogenicity in Human Populations
por: Dhanda, Sandeep Kumar, et al.
Publicado: (2018)

Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine
por: Mauldin, Ileana S, et al.
Publicado: (2015)

The number of CD34+CD38+CD117+HLA-DR+CD13+CD33+ cells indicates post-chemotherapy hematopoietic recovery in patients with acute myeloid leukemia
por: Gu, Runxia, et al.
Publicado: (2017)

Mutations in CD8 that affect interactions with HLA class I and monoclonal anti-CD8 antibodies
Publicado: (1991)

The CD4+/CD14+HLA-DRlo/neg ratio as a prognostic biomarker in cancer patients
por: Dietz, Allan B, et al.
Publicado: (2013)

Empty conformers of HLA-B preferentially bind CD8 and regulate CD8(+) T cell function
por: Geng, Jie, et al.
Publicado: (2018)

Expression of CD1a, CD207, CD11b, CD11c, CD103, and HLA-DR receptors on the surface of dendritic cells in the skin of patients with atopic dermatitis
por: Ścibior, Kinga, et al.
Publicado: (2017)

Relationship of the Content of Systemic and Endobronchial Soluble Molecules of CD25, CD38, CD8, and HLA-I-CD8 and Lung Function Parameters in COPD Patients
por: Kubysheva, Nailya, et al.
Publicado: (2017)

Uptake of HLA Alloantigens via CD89 and CD206 Does Not Enhance Antigen Presentation by Indirect Allorecognition
por: Breman, Eytan, et al.
Publicado: (2016)

Identification of patient-specific CD4(+) and CD8(+) T cell neoantigens through HLA-unbiased genetic screens
por: Cattaneo, Chiara M., et al.
Publicado: (2023)

Are Pathogenic Germline Variants in Metastatic Melanoma Associated with Resistance to Combined Immunotherapy?
por: Amaral, Teresa, et al.
Publicado: (2020)

Immunodominant Tuberculosis CD8 Antigens Preferentially Restricted by HLA-B
por: Lewinsohn, Deborah A, et al.
Publicado: (2007)

Human CD8 transgene regulation of HLA recognition by murine T cells
Publicado: (1995)

Direct evidence for binding of CD8 to HLA class I antigens
Publicado: (1989)

Corecognition of HLA-A1 and HLA-DPw3 by a human CD4+ alloreactive T lymphocyte clone
Publicado: (1990)

Kinetics of CD169, HLA-DR, and CD64 expression as predictive biomarkers of SARS-CoV2 outcome
por: Gatti, Arianna, et al.
Publicado: (2023)

Tumor mutation burden and circulating tumor DNA in combined CTLA-4 and PD-1 antibody therapy in metastatic melanoma – results of a prospective biomarker study
por: Forschner, Andrea, et al.
Publicado: (2019)

Immunodominant HIV-1-specific HLA-B- and HLA-C-restricted CD8+ T cells do not differ in polyfunctionality
por: Mkhwanazi, Nompumelelo, et al.
Publicado: (2010)

Potential Role for HIV-Specific CD38(−)/HLA-DR(+) CD8(+) T Cells in Viral Suppression and Cytotoxicity in HIV Controllers
por: Hua, Stéphane, et al.
Publicado: (2014)

Level of CD8 T Lymphocytes Activation in HIV-Infected Pregnant Women: In the Context of CD38 and HLA-DR Activation Markers
por: Musyoki, Stanslaus, et al.
Publicado: (2014)

Functional Change of Effector Tumor-Infiltrating CCR5(+)CD38(+)HLA-DR(+)CD8(+) T Cells in Glioma Microenvironment
por: Chen, Pin-Yuan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_7cq6br6mhjpetoqjoa65kcor40